Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Third Wave s PGx Test for Camptosar Adverse Events

NEW YORK, Aug. 24 (GenomeWeb News) - Third Wave this week received approval from the US Food and Drug Administration for a pharmacogenetic test that takes advantage of the recent re-labeling of a lucrative chemotherapy drug.


Third Wave claimed that its test is "the first pharmacogenetic test to be approved by the FDA for use as a companion diagnostic to a specific drug therapy," in a statement.


According to Third Wave, the FDA has cleared its Invader UGT1A1 molecular assay for use in identifying patients who may be at increased risk of adverse reaction to Pfizer's Camptosar, a chemotherapy drug for colorectal cancer.


The assay detects and identifies mutations in the UGT1A1 gene associated with that risk, and takes advantage of a recent re-labeling of Camptosar, which now includes dosing recommendation based on the patient's genetic profile.


Camptosar brought Pfizer first-quarter 2004 revenue of $212 million, up 132 percent compared to the same period in 2004, according to a statement from Pfizer. Sales in the United States account for about half of the drug's worldwide sales, Pfizer said.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.